Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Medical pioneer has educated his diabetes patients on how to get blood sugars to 83mg/dl, 24 hours a day
Read More »A Tribute to Richard K. Bernstein MD, FACE, FACN, FCCWS, on His 83rd Birthday
Liraglutide Gets FDA Indication For Reducing CVD Risk, But Not So Fast
The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.
Read More »ADA: Alum-GAD (Diamyd) Vaccine Fails to Prevent Type 1 Diabetes
Research will still continue due to its safety.
Read More »ADA: Basal Oral Insulin Tablet Reduces Fasting Blood Glucose and HbA1c Levels Similar to Insulin Glargine in Patients with Type 2
However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.
Read More »ADA: Effects of REMD-477, a Glucagon-Blocking Drug, in Patients with Type 1 Diabetes
Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.
Read More »ADA: Efficacy and Safety of Hybrid Closed-Loop Systems in Patients with Type 1 Diabetes
Results from two studies demonstrate improved glycemic control, reduction in nighttime- and exercise-induced hypoglycemia with the use of hybrid closed-loop systems.
Read More »My ADA Impressions: The Big Story
Why Google, Apple, and Amazon entering the diabetes market is the real big story from ADA.
Read More »ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes
Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.
Read More »ADA: Praluent® (alirocumab) Associated with Reducing Risk of Cardiovascular Disease in Type 2 Diabetes
Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.
Read More »GLP-1 Agonist Has CV Benefits
New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.
Read More »